N/A N=20 Floseal Treatment for Posterior Epistaxis Study
Epistaxis
Primary: Effectiveness of Floseal for the Treatment of Posterior Epistaxis. — 20 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=26 Management of Persistent Epistaxis Using Floseal Hemostatic Matrix
Epistaxis
Primary: Number of Participants With Initial Hemostasis — 10; 11 Participants — p=1.000
Phase 2 N=27 Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia
Hereditary Hemorrhagic Telangiectasia
Primary: Change in Assisted Epistaxis Severity Scale (aESS) Score From Baseline at 8 Week Follow-up — 2.32; 1.96 units on a scale
Phase 2 N=121 North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
Telangiectasia, Hereditary Hemorrhagic · Epistaxis
Primary: Frequency of Epistaxis — 7.0; 8.0; 7.5; 8.0 Bleeding episodes per week — p=0.97
N/A N=8 Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT)
Hereditary Hemorrhagic Telangiectasia (HHT) · Epistaxis
Primary: Epistaxis Severity Score (ESS) — 5.13; 3 score on a scale
N/A N=20 Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis
Epistaxis
Primary: This Study Evaluates the Efficacy of HemCon Hemostatic Agent in Control of Complicated Epistaxis in Terms of % Success of Hemostasis. Success Will be Defined as…
N/A N=68 The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.
Epistaxis · Blood Pressure
Primary: Change in Mean Arterial Blood Pressure — 5.1; 6.4; 4.6; 6.5 mmHg — p=0.42
Phase 2 N=20 Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Hereditary Hemorrhagic Telangiectasia (HHT)
Primary: Measurement of Epistaxis in Patients With HHT as Measured by the HHT Foundation Epistaxis Severity Score, Hematocrit, Hemoglobin and Serum Ferritin Levels.
Phase 2 N=18 Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia
Epistaxis · Hereditary Hemorrhagic Telangiectasia
Primary: Severityof Epistaxis — -0.4578; -1.4375 units on a scale
Phase 2 N=10 Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Hereditary Hemorrhagic Telangiectasia (HHT)
Primary: Epistaxis Using the Epistaxis Severity Score, Hematocrit, Hemoglobin and Serum Feritin Levels..
Phase 4 N=26 NOrth American Study for the Treatment of Recurrent epIstaxis With DoxycycLine: The NOSTRIL Trial
Epistaxis
Primary: Frequency of Epistaxis — -1.68; 1.14 Nosebleeds per week — p=0.16
Phase 4 N=40 Intranasal Bevacizumab for HHT-Related Epistaxis
HHT · Hereditary Hemorrhagic Telangiectasia · Epistaxis
Primary: Change in Epistaxis Severity Score (ESS) — -2.27; -1.16; -2.27; -1.01 score on a scale — p=0.111
Phase 2 N=50 Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hemorrhagic Hereditary Telangiectasia (HHT)
Hemorrhagic Hereditary Telangiectasia (HHT)
Primary: Percentage of Patients Experiencing an Improvement in Their Nosebleeds — 10; 9 Participants — p=<0.05
Phase 4 N=40 Comparing Blood Loss and Visualization After the Preoperative Use of Topical 0.05% Oxymetazoline Versus 1:1000 Epinephrine Prior to Endoscopic Sinus Surgery
Endoscopic Sinus Surgery · Nasal Polyps
Primary: Surgical Field Visualization During Sinus Surgery as Indicated by Score on Boezaart Grading Scale — 3; 2.55 score on a scale
Phase 2 N=144 Pomalidomide for the Treatment of Bleeding in HHT
Telangiectasia, Hereditary Hemorrhagic
Primary: Change From Baseline Epistaxis Severity Score — -1; -1.1; -1.3; -1.2 units on a scale
Phase 4 N=40 Effect of Tranexamic Acid on Postoperative Bleeding Following Sinus and Nasal Surgery
Chronic Sinusitis · Nasal Obstruction · Turbinate; Hypertrophy Mucous Membrane
Primary: Bleeding VAS - POD1 — 5.03; 4.82 score on a scale — p=0.8
N/A N=40 Nasal EPAP for Stroke Patients With Sleep Apnea: a Pilot Trial.
Ischemic Stroke · Obstructive Sleep Apnea
Primary: Apnea-hypopnea Index — 17.1; 25.2 apneas plus hypopneas per hour — p=0.183
Phase 3 N=18 Nasal Packing as a Drug Delivery System Postoperatively in Chronic Sinusitis With Polyposis
Chronic Sinusitis · Polyposis
Primary: Olfaction — 20.2; 19.8 units on a scale
N/A N=60 Efficacy of PuraSinus Versus Bioresorbable Nasal Dressings
Chronic Sinus Disease · Surgery
Primary: Pain During Debridement — 4; 5 Pain Score
Phase 3 N=66 Prophylactic Topical Epinephrine to Reduce Bleeding in Transbronchial Lung Biopsies
Lung Transplant; Complications, Mechanical · Lung Transplant; Complications · Bleeding
Primary: Intra-procedural Hemorrhage Grading by the Performing Bronchoscopist — 4; 13; 11; 24 Procedures
N/A N=60 A New Approach for Controlling Hemostasis During Canal Treatment
Blood Contamination of Root Canal During Endodontic Therapy
Primary: Change From Baseline in Root Canal Bleeding — 3.40; 3.73; 0.26; 3.03 millimeters — p=<.0001
Phase 3 N=408 Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis
Chronic Rhinosinusitis With Nasal Polyps
Primary: Change From Baseline in Total Nasal Polyp Score at Week 52 — -2.458; -0.380 Score — p=<.0001
N/A N=389 Long-term Control in Rhinosinusitis After Functional Endoscopic Sinus Surgery (FESS)
Condition of Patient 3 Years After FESS-operation
Primary: Control Status of Patients With Rhinosinusitis — 19.5; 36.8; 43.7 percentage of participants
Phase 4 N=45 Comparison of Topical Vasoconstriction in Endoscopic Sinus Surgery
Chronic Sinusitis
Primary: To Estimate the Change in Bleeding Category (Surgical Field Improvement) as Measured on a Six-point Scale, Measured From 0 (Best Case) to 5 (Worst Case). — 2.17; 2.04…
N/A N=37 The Efficacy of MEDIHONEY® for Chronic Rhinosinusitis With Nasal Polyposis After Functional Endoscopic Sinus Surgery
Chronic Sinusitis · Nasal Polyposis
Primary: Change in Lund-Kennedy Endoscopic Scores — -8.0; -1.5; -6.9 score on a scale
Phase 2 N=105 Mepolizumab in Nasal Polyposis
Nasal Polyps
Primary: Number of Participants With a Reduced Need for Surgery at Week 25 — 16; 5; 33; 46 Participants — p=0.003
N/A N=50 Posterior Nasal Nerve (PNN) Rhinitis Study
Chronic Rhinitis
Primary: Change in Reflective Total Nasal Symptom Score (rTNSS) — -5.1 units on a scale — p=<0.0001
Phase 2 N=10 A Study Evaluating the Efficacy and Safety of ARTISS Human Fibrin Sealant as Used in External Rhinoplasty
Subjects Requesting and Requiring an Open Rhinoplasty
Primary: Edema Severity — 1.25; 1.5; 1.25; 1 units on a scale
Phase 4 N=65 Nasal Decolonization for Orthopedic Trauma Patients
Surgical Site Infection
Primary: Number of Participants With Staphylococcus Aureus Nasal Colonization — 12 Participants
Phase 4 N=34 Nasonex (Mometasone Furoate Nasal Spray) in Adenoids Hypertrophy in Children (P04367)
Adenoids
Primary: Severity of Nasal Obstruction Symptoms at Baseline and Week 12 as Measured by the Total Clinical Score — 3.89; 1.26 Score on a scale